Stock Events

Stock Events

Mineralys Therapeutics 

$29.28
7
-$0.37-1.25% Tuesday 20:00

Statistics

Day High
30.86
Day Low
28.48
52W High
47.33
52W Low
12.87
Volume
662,332
Avg. Volume
-
Mkt Cap
2.32B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.13
-0.89
-0.64
-0.4
Expected EPS
-0.472157
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-355.62MNet Income

Analyst Ratings

53.5Average Price Target
The highest estimate is 56.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLYS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ardelyx
ARDX
Mkt Cap1.7B
Ardelyx focuses on kidney and cardiovascular diseases, directly competing in the same therapeutic areas as Mineralys Therapeutics.
Aurinia Pharmaceuticals
AUPH
Mkt Cap1.99B
Aurinia Pharmaceuticals develops drugs for kidney diseases and lupus, overlapping with Mineralys' focus on renal health.
Trevena
TRVN
Mkt Cap9,501
Trevena, Inc. develops therapies for central nervous system disorders but has interests in expanding to other areas including treatments that could compete with Mineralys.
Akebia Therapeutics
AKBA
Mkt Cap375.55M
Akebia Therapeutics focuses on kidney disease and anemia, areas that overlap with Mineralys Therapeutics' interests.
Amarin
AMRN
Mkt Cap295.04M
Amarin Corporation focuses on cardiovascular health, which can be indirectly competitive with Mineralys' focus on conditions that affect the heart and kidneys.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.77M
Galmed Pharmaceuticals works on liver diseases and metabolic disorders, which can intersect with Mineralys' therapeutic areas in terms of metabolic health and its impact on kidney function.

About

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Show more...
CEO
Mr. Jon Congleton
Employees
51
Country
United States
ISIN
US6031701013

Listings

XNAS
US
MLYS
BOATS
BOATS
MLYS.BOATS

0 Comments

Share your thoughts

FAQ

What is Mineralys Therapeutics stock price today?▼
The current price of MLYS is $29.28 USD — it has decreased by -1.25% in the past 24 hours. Watch Mineralys Therapeutics stock price performance more closely on the chart.
What is Mineralys Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mineralys Therapeutics stocks are traded under the ticker MLYS.
Is Mineralys Therapeutics stock price growing?▼
MLYS stock has risen by +14.55% compared to the previous week, the month change is a +3.72% rise, over the last year Mineralys Therapeutics has showed a +102.49% increase.
What is Mineralys Therapeutics market cap?▼
Today Mineralys Therapeutics has the market capitalization of 2.32B
What is Mineralys Therapeutics revenue for the last year?▼
Mineralys Therapeutics revenue for the last year amounts to 0 USD.
What is Mineralys Therapeutics net income for the last year?▼
MLYS net income for the last year is -355.62M USD.
How many employees does Mineralys Therapeutics have?▼
As of May 06, 2026, the company has 51 employees.
In which sector is Mineralys Therapeutics located?▼
Mineralys Therapeutics operates in the Health & Wellness sector.
When did Mineralys Therapeutics complete a stock split?▼
Mineralys Therapeutics has not had any recent stock splits.
Where is Mineralys Therapeutics headquartered?▼
Mineralys Therapeutics is headquartered in Radnor, United States.